Galectin Therapeutics (NASDAQ:GALT) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Galectin Therapeutics (NASDAQ:GALTGet Rating) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright dropped their price objective on Galectin Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, May 17th.

Shares of NASDAQ:GALT opened at $1.19 on Wednesday. Galectin Therapeutics has a 52-week low of $1.19 and a 52-week high of $4.40. The company has a market capitalization of $70.67 million, a P/E ratio of -2.05 and a beta of 1.64. The company has a 50-day simple moving average of $1.57 and a 200 day simple moving average of $1.98. The company has a debt-to-equity ratio of 79.37, a quick ratio of 4.63 and a current ratio of 3.51.

Galectin Therapeutics (NASDAQ:GALTGet Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). As a group, equities analysts forecast that Galectin Therapeutics will post -0.75 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the business. Centaurus Financial Inc. bought a new position in Galectin Therapeutics in the first quarter valued at about $34,000. Virtu Financial LLC bought a new position in Galectin Therapeutics in the fourth quarter valued at about $37,000. Commonwealth Equity Services LLC raised its position in Galectin Therapeutics by 59.2% in the first quarter. Commonwealth Equity Services LLC now owns 26,902 shares of the company’s stock valued at $43,000 after purchasing an additional 10,000 shares during the last quarter. Raymond James & Associates bought a new position in Galectin Therapeutics in the third quarter valued at about $51,000. Finally, Benjamin F. Edwards & Company Inc. raised its position in Galectin Therapeutics by 25.5% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 29,615 shares of the company’s stock valued at $61,000 after purchasing an additional 6,015 shares during the last quarter. Hedge funds and other institutional investors own 12.35% of the company’s stock.

Galectin Therapeutics Company Profile (Get Rating)

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Further Reading

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.